Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of eribulin plus bevacizumab as second-line therapy in HER2-negative metastatic breast cancer after bevacizumab + paclitaxel
2013-003194-10Phase 2Completed
- Sponsor
- Consorzio Oncotech
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin and bevacizumab in breast cancer, sponsored by Consorzio Oncotech. Primary endpoint: Overall response rate (ORR). Started Apr 2014; status: completed.
02
Drugs
eribulinbevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-003194-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003194-10.